stockrowPalvella Therapeutics, Inc.
PVLA Healthcare Biotechnology
Palvella Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.9 million.
- EPS
- −76.7%
- Free cash flow
- −136.4%
Quarter to June 2026, against a year earlier
Follow PVLA
Alert me
Palvella Therapeutics, Inc. (PVLA) Shares outstanding
Palvella Therapeutics, Inc.'s shares outstanding at the end of fiscal 2025 was $11.3M, up 405.4% from $2.2M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $14.4M. Over the past ten years it has ranged from $429.9K (fiscal 2015) to $11.3M (fiscal 2025) — the current reading is the highest in ten years. Palvella Therapeutics, Inc. ranks 433rd of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $11.3M | 405.44% |
| FY2024 | $2.2M | 24.08% |
| FY2023 | $1.8M | 93.49% |
| FY2022 | $927.2K | 14.92% |
| FY2021 | $806.8K | 18.47% |
| FY2020 | $681.0K | 7.62% |
| FY2019 | $632.8K | (4.63%) |
| FY2018 | $663.5K | 20.83% |
| FY2017 | $549.1K | 5.31% |
| FY2016 | $521.4K | 21.28% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $14.4M | 9.71% |
| Mar 2026 | $13.1M | 16.30% |
| Dec 2025 | $11.3M | 1.69% |
| Sep 2025 | $11.1M | 0.10% |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ADMA ADMA Biologics Inc compare | $225.8M |
| BHVN Biohaven Ltd. compare | $151.0M |
| AUPH Aurinia Pharmaceuticals Inc compare | $135.2M |
| IMNM Immunome, Inc. compare | $113.3M |
| CLDX Celldex Therapeutics, Inc. compare | $77.8M |
| VERA Vera Therapeutics, Inc. compare | $71.8M |
| PHVS Pharvaris N.V. compare | $68.1M |
| VCEL Vericel Corporation compare | $53.0M |
| PVLA Palvella Therapeutics, Inc. | $14.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on PVLA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement